Bärebring Linnea, Nwaru Bright I, Lamberg-Allardt Christel, Thorisdottir Birna, Ramel Alfons, Söderlund Fredrik, Arnesen Erik Kristoffer, Dierkes Jutta, Åkesson Agneta
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Krefting Research Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
Food Nutr Res. 2022 Oct 11;66. doi: 10.29219/fnr.v66.8842. eCollection 2022.
To assess whether supplementation with long chain n-3 fatty acids during pregnancy, lactation, or infancy reduces the risk of developing asthma or atopic disease during childhood.
Searches were performed in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus up to 2021-09-20, for randomized controlled trials (RCTs) that investigated the effect of supplemental long chain n-3 fatty acids during pregnancy, lactation, or infancy for the prevention of childhood asthma or allergy. Article selection, data extraction, and risk of bias assessment (Cochrane's Risk of Bias 2.0) were independently conducted by two assessors. The evidence was synthesized qualitatively according to the criteria of the World Cancer Research Fund and meta-analyzed.
A total of nine RCTs met inclusion criteria; six were conducted during pregnancy, two during infancy, and one during both pregnancy and infancy. Meta-analysis showed that long chain n-3 fatty acid supplementation during pregnancy significantly reduced the risk of asthma/wheeze in the child (RR 0.62 [95% confidence interval 0.34-0.91], = 0.005, = 67.4%), but not other outcomes. Supplementation during lactation of infancy showed no effects on any outcome. The strength of evidence that long chain n-3 fatty acid supplementation during pregnancy reduces risk of asthma/wheeze in the offspring was considered . No conclusion could be made for the effects of long chain n-3 fatty acid supplementation during pregnancy for other atopic diseases, or for supplementation during lactation or infancy for any outcome.
The intake of long chain n-3 fatty acid supplements during pregnancy may reduce the risk of asthma and/or wheeze in the offspring, but the strength of evidence is low. There is inconclusive evidence for the effects of long chain n-3 fatty acid supplements during pregnancy for other outcomes, as well as for supplementation during lactation or infancy.
评估孕期、哺乳期或婴儿期补充长链n-3脂肪酸是否可降低儿童患哮喘或特应性疾病的风险。
截至2021年9月20日,在MEDLINE、Embase、Cochrane对照试验中央注册库和Scopus中进行检索,查找研究孕期、哺乳期或婴儿期补充长链n-3脂肪酸对预防儿童哮喘或过敏作用的随机对照试验(RCT)。两名评估人员独立进行文章筛选、数据提取和偏倚风险评估(Cochrane偏倚风险2.0)。根据世界癌症研究基金会的标准对证据进行定性综合并进行荟萃分析。
共有9项RCT符合纳入标准;6项在孕期进行,2项在婴儿期进行,1项在孕期和婴儿期均进行。荟萃分析表明,孕期补充长链n-3脂肪酸可显著降低儿童患哮喘/喘息的风险(风险比0.62[95%置信区间0.34 - 0.91],P = 0.005,I² = 67.4%),但对其他结局无影响。哺乳期或婴儿期补充长链n-3脂肪酸对任何结局均无影响。孕期补充长链n-3脂肪酸可降低后代患哮喘/喘息风险的证据强度被认为是中等的。对于孕期补充长链n-3脂肪酸对其他特应性疾病的影响,或哺乳期或婴儿期补充长链n-3脂肪酸对任何结局的影响,均无法得出结论。
孕期摄入长链n-3脂肪酸补充剂可能会降低后代患哮喘和/或喘息的风险,但证据强度较低。关于孕期补充长链n-3脂肪酸对其他结局的影响,以及哺乳期或婴儿期补充长链n-3脂肪酸的影响,证据尚无定论。